GSK
GSK
721 hedge funds and large institutions have $9.73B invested in GSK in 2015 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 291 increasing their positions, 233 reducing their positions, and 63 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 291 | Existing positions reduced: 233
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
2% more call options, than puts
Call options by funds: $221M | Put options by funds: $218M
0.29% less ownership
Funds ownership: 4.13% → 3.84% (-0.29%)
3% less funds holding
Funds holding: 741 → 721 (-20)
16% less capital invested
Capital invested by funds: $11.6B → $9.73B (-$1.84B)
17% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$327M |
| 2 |
D.E. Shaw & Co
New York
|
+$81.1M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$58.9M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$45.2M |
| 5 |
Jane Street
New York
|
+$37.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$494M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$357M |
| 3 |
Barclays
London,
United Kingdom
|
-$189M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$115M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$105M |
GSK Hedge Fund Activity: Q2 2015 in Review
721 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2015, worth a combined $9.73B — down 16% from $11.6B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of GSK and 52 opened new positions — a net loss of 11 holders — while 233 trimmed existing stakes and 291 added.
The largest buyer was JP Morgan Chase, adding an estimated $327M. The largest seller was Dodge & Cox, cutting an estimated $494M.
- 721 institutional investors held GSK (GSK) as of Q2 2015, down from 741 in Q1 2015.
- Funds reported $9.73B of GSK stock for Q2 2015, down 16% quarter-over-quarter.
- 52 funds opened new GSK positions in Q2 2015 and 63 closed out, a net change of -11 holders.
- The largest GSK buyer in Q2 2015 was JP Morgan Chase, an estimated $327M added.
- The largest GSK seller in Q2 2015 was Dodge & Cox, an estimated $494M sold.
Based on aggregated 13F filings for Q2 2015.